UNSPSC 51273938: Epinephrine/lidocaine/povidone

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN204. This VA Drug Class (CN204) classifies this compound as belonging to the group LOCAL ANESTHETICS, INJECTION.

UNSPSC 51273938 Epinephrine/lidocaine/povidone is a Commodity code under which state and local governments procure emergency pharmaceuticals, naloxone products, and related medical supplies for community health and public safety initiatives. Recent solicitations show counties and state health agencies buying naloxone units, safe drug deactivation systems, and generic multi-source pharmaceuticals through competitive bidding and cooperative purchasing agreements. Issuing bodies include county health departments, state health and human services commissions, and multistate cooperative purchasing alliances serving participating municipalities and state agencies. The work ranges from direct purchase of specific naloxone and drug deactivation units to vendor qualification and pricing establishment for broader pharmaceutical distribution networks across state and local facilities.

Activity under the code concentrates in Florida and Minnesota, with emerging procurement interest in Texas. Seminole County, Florida issued IFB 60459723LAS (posted June 30, 2026, due July 26, 2023) to procure 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries to the county community health building; vendors must include delivery costs and maintain workers' compensation, commercial general liability, and professional liability insurance, with a two-year initial term plus one-year renewal option. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products across participating state and local facilities in Minnesota and Oregon, with awarded contracts effective July 1, 2026, and vendor pricing weighted at 75 percent of evaluation scoring. The Texas Health and Human Services Commission posted RFI HHS0017013 (April 3, 2026) to gather market intelligence on direct-to-manufacturer prescription fulfillment capabilities prior to issuing a formal RFP.